Jasper Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Mar 30, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 30, 2026

JSPR$14.75-9.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders’ Equity

(in thousands, except share data)

Common Stock · Additional Paid-In · Accumulated · Total Stockholders’
	Shares	Amount	Capital	Deficit	Equity
Balance as of December 31, 2023	11,163,896	$1	$248,039	$(169,600)	$78,440
Issuance of common stock upon exercise of stock options	33,735	—	329	—	329
Issuance of common stock through underwritten offering, net of discounts and commissions and issuance costs of $3.3 million	3,900,000	1	47,194	—	47,195
Issuance of common stock pursuant to Employee Stock Purchase Plan	29,491	—	360	—	360
Forfeiture of shares subject to earnout	(105,000)	—	—	—	—
Stock-based compensation expense	—	—	6,619	—	6,619
Net loss	—	—	—	(71,269)	(71,269)
Balance as of December 31, 2024	15,022,122	2	302,541	(240,869)	61,674
Issuance of common stock and pre-funded warrants through underwritten offering, net of issuance costs of $0.4 million	11,670,707	1	4,867	—	4,868
Issuance of common stock through ATM line, net of commissions and issuance costs of $0.3 million	1,231,447	—	6,454	—	6,454
Issuance of common stock for vested restricted stock units	12,000	—	—	—	—
Issuance of common stock pursuant to Employee Stock Purchase Plan	60,543	—	243	—	243
Stock-based compensation expense	—	—	6,713	—	6,713
Net loss	—	—	—	(75,801)	(75,801)
Balance as of December 31, 2025	27,996,819	$3	$320,818	$(316,670)	$4,151

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.